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INTRODUCTION
It has been estimated that up to 170,000 new cases of brain
metastases (BM) occur each year in the Unites States (1, 2),
and clinical studies have shown that between 20 and 30%
of patients with non-small cell lung cancer (NSCLC) devel-
op BM at some time during the course of their disease (3).
In the largest autopsy series performed to date, Posner and
Chernik examined the records of 2,375 cancer patients and
found that central nervous system metastases occur in approxi-
mately 24% of patients with systemic cancers (4). 
Some of these patients can be treated by craniotomy. His-
torically, some BM patients could be treated by craniotomy
for palliation, which has been usually combined with brain
irradiation. However, due to advances in surgical techniques,
more lesions are now considered accessible, and surgical com-
plications and post-surgical morbidity have been reduced.
Moreover, modern imaging techniques enable smaller metas-
tases to be located and defined, and allow operations to be
undertaken earlier during BM development.
Actually, brain metastatectomy offers certain advantages
over other therapeutic modalities (5). First, the excision of a
metastasis can immediately eliminate the effects of increased
intracranial pressure and the direct symptomatic effects on
surrounding brain tissues. Second, surgery provides tissue
for confirming a diagnosis of metastasis. Third, surgery may
establish a local cure or complete remission if all tumor cells
can be removed. 
However, despite the above advantages of BM surgery, it
has proven to offer limited benefits because of high recurrence
rates and short survival after resection. Therefore, when poten-
tial BM candidates for resection are considered, it is not possi-
ble to determine precisely who will benefit from surgical resec-
tion and post-resection treatment, because of the limited sur-
vival associated with metastatic brain tumors. Although some
guidelines for BM treatment, such as, ‘Clinical Practice Guide-
lines in Oncology’ by the National Comprehensive Cancer
Network (NCCN) (6), have been issued, many controversies
regarding treatment remain. Therefore, in an attempt to iden-
tify optimal candidates for brain metastatectomy, we retro-
spectively evaluated the clinical records of 25 patients who
survived for less than 3 months after brain metastatectomy,
and compared with all the patients who underwent brain
metastatectomy during same period at the same institutes.
MATERIALS AND METHODS
From January 1997 through July 2007, 83 patients with
a single BM lesion underwent craniotomy for brain tumor
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Clinical Analysis of Patients who Survived for Less than 3 Months 
After Brain Metastatectomy
In the patients with brain metastasis (BM), it is impossible to determine who will ben-
efit from surgery because of limited survival. In an attempt to identify optimal can-
didates for brain metastatectomy, we analyzed patients who survived for <3 months
after craniotomy for a single BM lesion. Between January 1st, 1997 and July 31st,
2007, 83 patients with a single BM underwent craniotomy. Of these patients, 25
patients (30.1%) died within 3 months of craniotomy. The primary lesions were non-
small call lung cancer in 15, colon cancer in 6, and breast cancer, renal cell carci-
noma, ovarian cancer, or esophageal cancer in one apiece. Of the 25 patients, 19
(79%) were of tumor stage IV and had extra-cranial metastasis. Eleven (44%) of
the 25 primary cancers had a well-controlled status. Twelve patients (48%) had a
Karnofsky Performance Scale (KPS) score of <70, and 13 (52%) were of Recur-
sive Partitioning Analysis (RPA) class 3. Primary cancer status, RPA class, and
functional status were found to be critical factors for consideration when selecting
surgical candidates. In addition, adjuvant therapy was found to have an important
role on survival.
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sity Medical Center. Before brain metastatectomy, we expect-
ed all 83 patients to survive for >12 weeks based on their
preoperative medical conditions, but as many as 25 (30.1%)
died within 3 months of craniotomy. 
Clinical characteristics of patients
A retrospective analysis was performed on the clinical vari-
ables of the 25 cases that died within 3 months of cranioto-
my. These variables included patient age and gender, type of
primary cancer, primary tumor stage, presence of extra-cra-
nial metastasis, status of primary cancer, Karnofsky Perfor-
mance Scale (KPS) score (7), and Recursive Partitioning Anal-
ysis (RPA) class. 
According to the classification devised by Gaspar et al. (8),
patients in RPA class 1 are characterized by an age of <65 yr,
a KPS score of ≥70, the absence of extra-cranial metastases,
and good control of systemic disease. RPA class 2 patients
have a KPS score of ≥70, but may also have an age of ≥65
yr, or uncontrolled systemic disease or systemic metastases.
Patients in RPA class 3 are those with a KPS score of <70.
Features of brain lesion
The parameters in the 25 patients examined included metas-
tasis timing, size and location of BM, and functional grade
of brain lesion. Brain metastases diagnosed <60 days after
primary lesion diagnosis were considered synchronous metas-
tases, and those diagnosed ≥60 days of primary lesion diag-
nosis were considered metachronous metastases. Sizes of BM
were defined as maximal orthogonal diameter in T1 weighted
gadolinium (Gd) enhanced magnetic resonance (MR) images.
Locations of BM were categorized as supratentorial or infraten-
torial. Each tumor was functionally graded by preoperative
MRI in terms of location with respect to the eloquent brain
according to the scheme developed at the M.D. Anderson
Cancer Center (9). Functional grade I tumors were located
in non-eloquent brain regions (e.g., frontal or temporal polar
areas), grade II tumors near eloquent brain regions (e.g., near
the motor or sensory cortex, calcarine fissure, speech center,
dentate nucleus, brain stem, or corpus callosum) and grade
III tumors were located in eloquent brain regions (e.g., motor
and sensory cortex, visual center, speech center, internal cap-
sule, basal ganglia, hypothalamus, thalamus, brain stem, or
dentate nucleus).
Surgical indications
Clinical indications included symptoms and signs of in-
tracranial hypertension unresponsive to adequate medical
therapy, (e.g., corticosteroid and mannitol), intractable seizures,
reduced level of consciousness, progressive motor weakness,
gait ataxia, or aphasia. Neuro-imaging indications included
lesion enlargement, associated hemorrhage, and a mass effect
due to edema unresponsive to maximal medication.
All the 25 patients had life expectancies of >12 weeks and
had not undergoing investigational therapies during the pre-
ceding 3 weeks. Patients that had undergone prior irradia-
tion and those with leptomeningeal tumor involvement were
excluded.
Outcomes and data analysis
The medical records, i.e., clinical history, operative and
pathology reports, and radiographic studies, of the 25 pati-
ents were analyzed, and dates of death were confirmed for
all patients that succumbed.
Survival times were calculated from the dates of BM surgery
to death. In addition, dates of primary cancer diagnosis, dates
of BM diagnosis, dates of brain metastatectomy, and dates
of death were recorded, and times between these dates were
calculated. Overall survival was defined as time from date of
primary cancer diagnosis to death.
Post-surgical imaging studies were reviewed for evidence
of central nervous system (CNS) progression. On Gd enhanced
T1 weighted MR images, CNS progression was defined as
the appearance of a new enhancing brain lesion including
original BM resection site, or in the spinal cord or cerebro-
spinal fluid. In the patients that died, cause of death and date
of death were recorded. Causes of death were categorized as
CNS-related if a patient had stable systemic disease but suc-
cumbed to progressive intra-cranial disease and associated
progressive neurological dysfunction. When a patient suc-
cumbed to progressive primary cancer, cause of death was
categorized as primary cancer-related. 
Statistical analysis 
Statistical analyses were performed using SSPS version 12.0
(SPSS Institute, Inc., Chicago, IL, U.S.A.). Overall survivals
were estimated using Kaplan-Meier methods. The Cox regres-
sion analysis was used to adjust the factors affecting survival.
Variables found to be significantly associated with survival
by univariate analyses were subjected to multivariate analy-
ses. The chi-square tests were used to compare the two groups
in terms of baseline characteristics. Results were considered
significant when Pvalues were less than 0.05. 
RESULTS
Characteristics of the study population
Table 1 details patient characteristics and Table 2 shows
summary. There were 19 male (76%) and 6 female (24%)
patients of mean age 59.1 yr (range 39-71). The types of pri-
mary cancer follows; 15 (60%) NSCLC, 6 (24%) colon can-
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ovarian cancer, and 1 (4%) esophageal cancer. In term of pri-
mary tumors without considering BM, 3 patients (12%) had
a tumor stage of IIB, 3 (12%) a tumor stage of IIIB and 19
(76%) had a tumor stage of IV. Nineteen patients (76%) had
extra-cranial metastasis. Eleven of the 25 primary cancers had
a well-controlled status (44%), and 14 did not (56%). Twelve
patients (48%) had a KPS score of <70 and 13 patients (52%)
had a KPS score ≥70. Only one patient (4%) was of RPA
class 1, 11 (44%) were of RPA class 2, and 13 (52%) were
of RPA class 3.
As was expected, these 25 patients who survived for less
than 3 months after craniotomy had higher rates of extra-cra-
nial metastasis, progressive primary disease, a KPS score of
<70, and RPA class 3 than all the patients who underwent
brain metastatectomy during same period at the same insti-
tutes (P<0.05). These factors were associated with survival
in the univariate analysis using Cox regression model. But,
in the multivariate analysis, there was no statistical signifi-
cance in the extracranial metastasis (P=0.067). Table 6 shows
the relationship between survival and clinical factors.
Features of brain lesions
Table 3 shows the detailed clinical features of brain lesions
and Table 4 provides a summary. Brain lesions were <3 cm
in 13 patients (52%) and ≥3 cm in 12 (48%). Twenty BMs
(80%) were located in the supratentorial region and 5 (20%)
in the infratentorial region. Two tumors (8%) were of func-
tional grade 1, 10 (40%) tumors in functional grade 2, and
the other 13 (52%) in functional grade 3. Six patients (24%)
experienced synchronous development and 19 (76%) me-
tachronous development.  
Furthermore, patients who survived for less than 3 months
were more likely to have a BM of <30 mm in size and to be
of functional grade 3 than all the patients who underwent
brain metastatectomy during the same period at the same
institutes. Functional grade of BM location had statistical
significance on survival in the univariate analysis (P=0.033)
but did not in the multivariate analysis after multi-factor
adjustment (P=0.078). Other features of BM did not have
an influence of the survival in the univariate and multivari-
ate (Table 7).
Treatment before and after brain metastatectomy
Table 5 details the patients who received adjuvant and neo-
adjuvant therapy. Nineteen patients (76%) did not receive any
treatment for primary systemic cancer or BM before metasta-
tectomy. One patient (4%) received systemic chemotherapy
alone and another received brain irradiation alone before brain
metastatectomy. Four patients (16%) received both. After
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KPS, karnofsky performance scale; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma; RPA, recursive partitioning analysis.
No. Primary
cancer
Sex/age
(yr)
Stage of 
cancer
Extracranial
metastasis
Status of 
primary cancer
KPS score
RPA
class
1 F/49 Breast IV Lung, Liver, Bone Under-control <70 3
2 F/51 Colon IV Lung, Liver, Kidney Under-control ≥70 2
3 M/52 Colon IV Liver, Kidney Under-control <70 3
4 M/57 Colon IV Lung, Bone Out-of-control <70 3
5 M/53 Colon IV Lung, Bone Under-control ≥70 2
6 M/66 Colon IV Lung Out-of-control ≥70 2
7 M/65 Colon IV Lung Out-of-control <70 3
8 M/63 Esophagus IV Liver Under-control <70 3
9 F/71 NSCLC IIIB (-) Out-of-control ≥70 2
10 M/56 NSCLC IV Bone Under-control ≥70 2
11 F/65 NSCLC IIIB (-) Under-control <70 3
12 F/71 NSCLC IV Adrenal gland Out-of-control ≥70 2
13 M/51 NSCLC IIB (-) Out-of-control <70 3
14 M/51 NSCLC IV Bone Out-of-control ≥70 2
15 M/64 NSCLC IIB (-) Under-control ≥70 1
16 M/69 NSCLC IV Adrenal gland Out-of-control <70 3
17 M/58 NSCLC IV Adrenal gland Under-control <70 3
18 M/59 NSCLC IV Bone, Liver Out-of-control ≥70 2
19 M/39 NSCLC IIIB (-) Out-of-control ≥70 2
20 M/56 NSCLC IIB (-) Out-of-control <70 3
21 M/50 NSCLC IV Bone Out-of-control <70 3
22 M/69 NSCLC IV Adrenal gland Out-of-control ≥70 2
23 M/60 NSCLC IV Spine Under-control ≥70 3
24 F/68 Ovary IV Lung Under-control <70 3
25 M/64 RCC IV Lung, Bone Out-of-control ≥70 2
Table 1. Features of patients who survived for less than 3 months after brain metastatectomymetastatectomy, 12 patients (48%) did not receive adjuvant
therapy, 7 patients (28%) received chemotherapy alone, 4
(16%) received brain irradiation alone, and the remaining 2
(8%) received both modalities after brain surgery. 
Of the six patients who experienced synchronous BM devel-
opment, two patients received neoadjuvant therapy before
brain metastatectomy. One received neoadjuvant brain radio-
therapy after BM diagnosis but before craniotomy, and the
other received neoadjuvant chemotherapy and radiotherapy
instead of immediate brain metastatectomy.
Patients who survived for less than 3 months were less like-
ly to receive neoadjuvant and adjuvant therapy than all the
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No.
Size
(mm)
Functional
grade
Adjuvant Location Timing of BM
1 35 Supratentorial 3 Metachronous (-)
2 21 Infratentorial 2 Metachronous CTX
3 21 Supratentorial 3 Metachronous RTX
4 40 Supratentorial 3 Metachronous (-)
5 35 Supratentorial 2 Metachronous (-)
6 32 Infratentorial 2 Metachronous (-)
7 21 Supratentorial 3 Metachronous (-)
8 20 Supratentorial 3 Metachronous RTX
9 40 Supratentorial 2 Synchronous RTX
10 29 Supratentorial 2 Metachronous (-)
11 24 Infratentorial 3 Metachronous CTX
12 25 Supratentorial 3 Metachronous (-)
13 25 Supratentorial 3 Metachronous (-)
14 35 Infratentorial 2 Synchronous (-)
15 28 Supratentorial 3 Metachronous RTX, CTX
16 33 Supratentorial 2 Metachronous (-)
17 20 Supratentorial 2 Synchronous CTX
18 35 Supratentorial 1 Synchronous CTX
19 45 Supratentorial 1 Metachronous RTX
20 50 Supratentorial 3 Metachronous RTX, CTX
21 35 Infratentorial 2 Synchronous CTX
22 18 Supratentorial 1 Metachronous CTX
23 22 Supratentorial 3 Metachronous (-)
24 60 Supratentorial 3 Metachronous CTX
25 15 Supratentorial 1 Synchronous (-)
Table 3. Characteristics of brain metastases of the patients who
survived for less than 3 months after brain metastatectomy (BM)
CTX, chemotherapy; RTX, radiotherapy.
*The proportion of grade 3 in the patients who survived less than 3 months
after brain metastatectomy was higher than that in the all the patients who
underwent brain metastatectomy with statistical significance.
All the
patients who
underwent
brain
metastatec-
tomy
(n=83)
Patients who
survived for 
<3 months
after brain
metastatec-
tomy
(n=25)
P
value
Size of BM
<30 mm 27 (32.5%) 13 (52.0%) <0.05
≥30 mm 56 (67.5%) 12 (48.0%)
Location of BM
Supratentorial 67 (80.7%) 20 (80.0%)
Infratentorial 16 (19.3%) 5 (20.0%)
Functional grade of BM location
1 21 (25.3%) 2 (8.0%) <0.05*
2 43 (51.8%) 10 (40.0%)
3 19 (22.9%) 13 (52.0%)
Timing of BM
Synchronous 28 (33.7%) 6 (24.0%)
Metachronous 55 (66.3%) 19 (76.0%)
Table 4. Summary of characteristics of brain metastasis (BM)
KPS, karnofsky performance scale; RPA, recursive partitioning analysis.
All the
patients who
underwent
brain
metastatec-
tomy
(n=83)
Patients who
survived for 
<3 months
after brain
metastatec-
tomy
(n=25)
P
value
Gender
Male 67 (80.7%) 19 (76.0%)
Fmale 16 (19.3%) 6 (24.0%)
Age (yr)
Mean 58.7 59.1
Range 31-72 39-71
≥65 31 (37.3%) 8 (32.0%)
<65 52 (62.7%) 17 (68.0%)
Primary cancer
Non-small cell lung cancer 48 (57.8%) 15 (60.0%)
Colon cancer 14 (16.9%) 6 (24.0%)
Breast cancer 7 (8.4%) 1 (4.0%)
Renal cell carcinoma 7 (8.4%) 1 (4.0%)
Hepatocellular carcinoma 2 (2.4%) 0 (0.0%)
Stomach cancer 2 (2.4%) 0 (0.0%)
Ovarian cancer 2 (2.4%) 1 (4.0%)
Esophageal cancer 1 (1.2%) 1 (4.0%)
Stage of primary cancer
IIB 7 (8.4%) 3 (12.0%)
IIIA 10 (12.0%) 0 (0.0%)
IIIB 23 (27.7%) 3 (12.0%)
IV 43 (51.8%) 19 (76.0%)
Extra-cranial metastasis
Presence 43 (51.8%) 19 (76.0%) <0.05
Absence 40 (48.2%) 6 (24.0%)
Status of primary cancer
Under-control 52 (62.7%) 11 (44.0%) <0.05
Out-of-control 31 (37.3%) 14 (56.0%)
KPS score
≥70 64 (77.1%) 13 (52.0%) <0.05
<70 19 (22.9%) 12 (48.0%)
RPA class
1 22 (26.5%) 1 (4.0%) <0.05
2 42 (50.6%) 11 (44.0%)
3 19 (22.9%) 13 (52.0%)
Table 2. Summary of clinical features of patientspatients who underwent brain metastatectomy during same
period. But in the Cox regression analysis (Table 6), neoad-
juvant (P=0.034) and adjuvant treatment (P=0.005) had
statistically significant influences on the survival in the uni-
variate analysis. But after multi-factor adjustment in the mul-
tivariate analysis, adjuvant treatment alone had statistical
association with survival; the Hazard ratio of survival for the
patients who did not received adjuvant therapy versus the
patients who received adjuvant treatment was 2.89 (95%
confidence interval, 1.16-5.26; P=0.023).
Clinical course
Fig. 1 details survivals. Mean survival after date of primary
cancer diagnosis was 9.90 months (range, 2.30-30.70); 4.25
months (range, 2.30-8.47) in those that experienced syn-
chronous BM development, and 13.4 months (range, 5.57-
30.70) in those that experienced metachronous BM devel-
opment.
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*Chemotherapy and radiotherapy with separated interval; 
� In the patients
who survived less than 3 months after brain metastatectomy, neoadjuvant
and adjuvant therapy were not performed more than in the all the patients
who underwent brain metastatectomy with statistical significance.
All the
patients who
underwent
brain
metastatec-
tomy
(n=83)
Patients who
survived for
<3 months
after brain
metastatec-
tomy
(n=25)
P
value
Neoadjuvant  Not-performed 30 (36.1%) 19 (76.0%) <0.05
�
therapy Perform
Chemotherapy alone 41 (49.4%) 1 (4.0%)
Radiotherapy alone 7 (8.4%) 1 (4.0%)
Both* 5 (6.0%) 4 (16.0%)
Adjuvant   Not-performed 13 (15.7%) 12 (48.0%) <0.05
�
therapy Perform
Chemotherapy alone 29 (34.9%) 7 (28.0%)
Radiotherapy alone 14 (16.9%) 4 (16.0%)
Both* 27 (32.5%) 2 (8.0%)
Table 5. Treatment before and after brain metastasectomy
Factors
Median
survival
(month)
Uni-
variate
analysis
(P value)
Hazard
ratio
(95% CI)
Multi-
variate
analysis
(P value)
Hazard
ratio
(95% CI)
Gender
Male NR 0.250 1.33 NA
Female NR (0.80, 2.16)
Age
≥65 yr NR 0.181 1.39 NA
<65 yr NR (0.86, 2.26)
Pathology
NSCLC 9.8 0.083 1.54    NA
Non-NSCLC NR (0.94, 2.50)
Extracranial metastasis
Presence 8.0 0.033 1.75    0.067 1.32
Absence NR (1.04, 2.96) (1.19, 2.28)
Primary cancer
Under-control NR 0.024 1.77    0.013 1.94  
Out-of-control 7.1 (1.07, 2.91) (1.15, 3.27)
KPS score
≥70 NR 0.003 2.04    0.000 12.76
<70 3.6 (1.26, 3.32) (3.36, 46.43)
RPA class
1 or 2 NR 0.017 2.18    0.020 2.89   
3 8.4 (1.31, 6.02) (1.62, 8.03)
Neoadjuvant treatment
Performed NR 0.034 2.7     0.263 1.20   
Not-performed NR (1.04, 7.03) (0.15, 9.94)
Adjuvant treatment
Performed NR 0.005 2.61    0.023 2.89   
Not-performed 5.4 (1.29, 5.26) (1.16, 7.23)
Table 6. Clinical factors of patients affecting survival in univari-
ate and multivariate analysis using Cox regression model
CI, confidence interval; KPS, Karnofsky Performance Scale; NA, not-
assessed; NSCLC, non-small cell lung cancer; NR, not-reached to medi-
an survival time; RPA, Recursive Partitioning Analysis.
Factors
Median
survival
(month)
Uni-
variate
analysis
(P value)
Hazard
ratio
(95% CI)
Multi-
variate
analysis
(P value)
Hazard
ratio
(95% CI)
Size of BM
<3 cm 8.6 0.048 1.94 0.064 1.79
≥3 cm NR (0.97, 3.88) (1.04, 2.98)
Location of BM
Supratentorial NR 0.734 1.14 NA
Infratentorial NR (0.60, 3.56)
Functional grade of BM
1 or 2 NR 0.033 1.88    0.078 1.42   
3 7.8 (0.89, 3.70) (0.94, 3.14)
Timing of BM
Synchronous NR 0.134 1.79 NA
Metachronous NR (0.83, 3.87)
Table 7. Factors of brain lesions, adjuvant and neoadjuvant treat-
ment affecting survival in univariate and multivariate analysis
using Cox regression model
BM, brain metastasis; CI, confidence interval; NA, not-assessed; NR,
not-reached to median survival time.
Cancer-
related 
death
(n=16)
CNS-
related 
death
(n=3)
Systemic
complication 
related death
(n=6)
None (n=12) 9 (75.0%) 1 (8.3%) 2 (16.7%)
Chemotherapy alone (n=7) 4 (57.1%) 1 (14.3%) 2 (28.6%)
Radiotherapy alone (n=4) 2 (50.0%) 1 (25.0%) 1 (25.0%)
Both* (n=2) 1 (50.0%) 0 (0.0%) 1 (50.0%)
Table 8. Causes of deaths according to adjuvant therapy
*Chemotherapy and radiotherapy with separated interval.Mean survival after craniotomy was 2.06 months (range,
0.67-2.93); 2.20 months (range, 1.50-2.60) in those that
experienced synchronous BM development, and 2.02 months
(range, 0.67-2.93) in those that experienced metachronous
BM development.
Mean time-interval between the date of primary cancer
diagnosis and the date of BM diagnosis was 7.54 months
(range, 0.00-27.67); and 0.40 months (range, 0.00-1.60) in
those that experienced synchronous BM development, and
9.79 months (range, 3.60-27.67) in those that experienced
metachronous BM development.
Mean time-interval between the date of BM diagnosis and
craniotomy was 1.62 months (range, 0.00-9.57); and 1.26
months (range, 0.00-5.53) in those that experienced synch-
ronous BM development, and 1.73 months (range, 0.00-9.57)
in those that experienced metachronous BM development. 
Analysis of cause of death
Sixteen of the 25 patients died from primary cancer pro-
gression; multiple organ failures due to multiple metastases,
which included malignant pleural effusion, neoplastic pneu-
monitis, renal failure, adrenal failures, and hepatic failures.
Three patients succumbed to direct CNS-related progression;
multiple distant metastasis or leptomeningeal metastases.
Six patients suffered from systemic complications, e.g., pneu-
monia or sepsis, due indirectly to immobilization due to neu-
rological dysfunction after brain surgery or brain irradiation
or from reduced immunity due to chemotherapy. Table 8
details causes of death by adjuvant therapy modality.
DISCUSSION
The prognosis of BM patients is poor, and if untreated, its
natural course involves progressive neurological deterioration
with a median survival time of 1-2 months (10). However,
surgical removal of a solitary BM prolongs survival and im-
proves quality of life (11), although median overall survival
for patients that undergo BM resection is only 4-7.7 months
(10). Nevertheless, patients with metachronous BM have a
substantially better prognosis after successful brain metasta-
tectomy with estimated 5-yr survivals of 21-45% (12, 13).
But, in synchronous BM patients, reports have shown con-
siderably dismal results after resection of the BM (14, 15).
Five-year survival rates of only 5-10% with a median survival
of less than 10 months have been reported for synchronous
BM patients treated by brain metastatectomy alone (16).
Occasionally, BM has life-threatening mass effects and caus-
es focal neurological deficits that may considerably decrease
functional grade. Thus, debulking can provide immediate
symptom relief and improve patient quality of life. However,
despite the benefits of surgical resection, surgical candidates
cannot be defined clearly. The traditional criteria used to select
patients who will benefit from surgery include a good phys-
ical function (as assessed using KPS scores), a single and sur-
gically accessible metastasis, and stable or absent extra-cra-
nial metastases. Allen K. Sills (17) recommended that the
following factors be evaluated when considering surgery in
BM patients; a single tumor, surgical accessibility, good tumor
localization, a young age, a KPS score of 70 or more, RPA
class 1, control of extra-cranial disease, confirmation of tis-
sue histology, need for immediate tumor debulking, large
tumor size, an undiagnosed primary tumor, a long disease-
free interval, and the absence of leptomeningeal involvement.
In the present study, as was expected, these patients who
survived for less than 3 months after craniotomy tended to
have more progressive primary cancer, higher rate of a KPS
score of <70, RPA class 3, and extra-cranial metastases, such
as, to the adrenal gland, bone, liver, or spine. In terms of size,
although BM may be small, an eloquent location often leads
to neurological dysfunction, and therefore, we decided to resect
BM to improve neurological deficit, such as motor weakness.
However, in these cases, most neurological deficits were not
recovered after surgery. Therefore, these twelve patients (48%)
could not received adjuvant therapy due to a deterioration of
performance status, and then, primary cancers or brain dis-
ease progressed in these patients. Additionally, many studies
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Fig. 1. Survival and time-intervals during clinical course of patients
who survived less than 3 months after brain metastatectomy.
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Dx of primary cancer Dx of BM Metastatectomy Deathhave shown that radiosurgery such as Gamma Knife Radio-
surgery or Cyberknife is effective at controlling BM and pro-
longed survival (18-21), especially in case of small sized lesions.
In this study, although brain lesion was small in size, most
of patients who suffered from severe cerebral edema with risk
of impending brain herniation and acute neurological deter-
iorations without response to medical treatment were treated
with surgical decompression in order to prevent CNS-relat-
ed death.
In the patients who succumbed to systemic complications,
causes of death were aspiration pneumonia or adult respira-
tory distress syndrome after post-surgical or post-irradiative
hemiparesis or sepsis during chemotherapy. In fact, patients
who could not be administered adjuvant therapy had a poor-
er condition before and after brain metastatectomy, such as
postoperative progression of neurological dysfunction and a
poor general condition. Therefore, they could not receive any
further treatment, and for these reasons primary cancers pro-
gressed. 
In terms of adjuvant therapy, Macchiarini et al. (22) showed
that systemic chemotherapy is the most significant indepen-
dent predictor of disease-free long-term survival after brain
metastasectomy. Our result that adjuvant treatment had an
influence on survival concur with that of Macchiarini et al.
(22) Patchell et al. (23) demonstrated recurrence and neuro-
logical death is less likely in patients treated with brain meta-
statectomy with following whole brain radiotherapy. Deter-
mining critical candidates for brain metastatectomy can im-
prove survival in some patients and provide an opportunity
for further treatment. In fact, the status of systemic disease
is extremely important since most patients who undergo sur-
gery for brain metastases eventually succumb to systemic
disease, often without BM recurrence (24). These days many
authors appear to view systemic chemotherapy as an impor-
tant therapeutic modality that offers therapeutic benefit to
BM patients (25-28).
It is difficult to advise on the role of neoadjuvant therapy
in cases of brain metastasis based on the findings of the pre-
sent study. Some differences in the neoadjuvant therapy were
found between patients who survived for less than 3 months
after brain metastatectomy and all the patients who under-
went brain metastatectomy during the same period at the
same institutes. But, treatment before BM diagnosis was con-
sidered in all the patients who underwent brain metastatec-
tomy, therefore, more patients were found to receive neoad-
juvant therapy. It is a fact that many patients should experi-
ence primary cancer progression in brain during systemic
therapy for primary cancer, but the exact number was not
calculated during the present study. Anyway, it is less mean-
ingful that more patients who survived for less than 3 months
might not perform neoadjuvant therapy in this study.
However, in the Kaplan-Meier survival analysis, median
survival times of patients in analyzed many factors of Cox
regression model did not reach median value, which suggest-
ed either the need for longer follow-up periods or the need
for larger number of patients.
We failed to identify a time of BM onset during the expect-
ed clinical course of systemic cancer. If the time of BM occur-
rence during an expected survival period could be predicted,
we would be able to precisely calculate remaining survival
times. For example, if a BM occurs in a patient who diagnosed
lung cancer 3 yr ago, and his survival was expected to 5 yr
at that time, his remnant survival is 2 yr now. In this patient,
brain metastatectomy can help to guarantee remnant sur-
vival. But, if BM occurs at 5 yr after diagnosis of lung can-
cer in this patient, brain surgery cannot help secure survival. 
However, in the present study, too few patients were en-
rolled to perform this assessment. Thus, more clinical data
is required to enable us to predict the timing of BM during
the clinical course after a primary cancer diagnosis.
In conclusion, although this study was limited in scope,
we assessed the features of patients that survived for 3 months
or less after surgical resection for single brain metastasis, and
compared with all the patients who underwent brain metasta-
tectomy during same period at the same institutes. Status of
primary cancer, RPA class, and functional status of patients
are critical factors when selecting surgical candidates. After
brain metastatectomy, good functional status which enabled
the patients to undergo appropriate adjuvant therapy might
be important to prolong survival in BM patients. Neurosur-
geons must perform brain metastatectomy so as not to cause
neurological complications that may cause sufficient deterio-
ration to prevent subsequent adjuvant therapy on the base of
individual conditions.
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